4506 — Sumitomo Pharma Share News
0.000.00%
Last trade - 00:00- ¥826bn
- ¥902bn
- ¥453bn
Roivant's anti-inflammatory drug succeeds in mid-stage study
Brief: Roivant Announces Positive Neptune Study Results For Brepocitinib In NIU
Enters Into An Agreement To Amend Worldwide Collaboration And License For Four Compounds Including Ulotaront With Otsuka
Brief: Sumitomo Pharma, Pfizer Canada Announce Availability Of MYFEMBREE In Canada
Table: Sumitomo Pharma -9-MTH group results (IFRS)
Brief: European Commission Approves Commercialisation of RYEQO for Symptomatic Treatment of Endometriosis
Table: Sumitomo Pharma -6-MTH group results (IFRS)
Brief: Sumitomo Pharma Announces Authorization In Canada Of Orgovyx (Relugolix) For The Treatment Of Men With Advanced Prostate Cancer
Brief: Sumitomo Pharma Co Ltd Orgovyx Is Expected To Be Available For Prescription In Canada In Q1 2024
Brief: Sumitomo Pharma and Pfizer in Canada Receive Health Canada Approval for MYFEMBREE
Primary Endpoints In Phase-3 Clinical Study
Table: Sumitomo Pharma -Q1 group results (IFRS)
Sumitomo Pharma And Otsuka Announce Topline Results From Phase 3 Diamond1 And Diamond2 Clinical Studies Evaluating Ulotaront In Schizophrenia
Table: Sumitomo Pharma -2022/23 group results (IFRS)
Table: Sumitomo Pharma -2022/23 parent results
Brief: Sumitomo Pharma Co Ltd Notification Of Valuation Loss On Shares Of Subsidiaries And Affiliates In Company's Non-Consolidated Financial Statements
Table: Sumitomo Pharma -2022/23 group forecast(IFRS)
Brief: Sumitomo Pharma Oncology Receives Orphan Drug Tag For Bone Cancer Drug
Promotion Agreement In Japan With Sumitomo Pharma For Izcargo I.V. Infusion 10 Mg